{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:49:27Z","timestamp":1787968167913,"version":"build-2784847793"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar University Internal","award":["QUCG-CHS-24\/25-541"],"award-info":[{"award-number":["QUCG-CHS-24\/25-541"]}]},{"name":"Qatar University Internal","award":["QUCG-CMED-25\/26-733"],"award-info":[{"award-number":["QUCG-CMED-25\/26-733"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Breast cancer presents with distinct clinical and molecular characteristics in the Middle East and North Africa (MENA) region, where women are diagnosed at younger ages and with more aggressive disease compared to Western populations. Despite the global burden, genomic studies of breast cancer in MENA remain underrepresented. This systematic review provides the first comprehensive analysis of somatic mutations in breast cancer patients across the MENA region.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following PRISMA guidelines, we analyzed 44 studies encompassing 13 MENA countries, representing data from over 2500 breast cancer patients. Studies were rigorously assessed using the Newcastle-Ottawa Scale, with mutation data extracted, standardized, and classified according to pathogenicity using established databases. We employed multiple sequencing methodologies, including next-generation sequencing and targeted gene panels, to identify country-specific and region-wide mutation patterns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 559 mutations across 104 genes, with TP53 (23.79%) and PIK3CA (10.19%) emerging as the most frequently altered genes, followed by significant mutations in BRCA1\/2, ATM, ESR1, and PTEN. Nearly 43% of variants were classified as pathogenic\/likely pathogenic, while 23% remained variants of uncertain significance. Missense mutations predominated (60.29%), followed by frameshift variants (13.06%) and stop-gained mutations (10.91%). We discovered distinctive country-specific mutation profiles, including unique alterations in KLF6 (Turkey) and IL-1\u03b2 (Iraq), reflecting potential environmental and hereditary influences unique to MENA populations. Notably, all 11 PIK3CA hotspot mutations that predict sensitivity to alpelisib therapy were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study reveals both shared and distinct somatic mutation patterns in MENA breast cancer patients compared to Western populations. The high prevalence of clinically actionable mutations, particularly in PIK3CA and DNA repair genes, presents immediate opportunities for implementing targeted therapies across the region. Our findings underscore the urgent need for establishing a MENA Breast Cancer Genomics Consortium to standardize sequencing protocols, develop locally validated gene panels, and create regional variant databases that capture the unique mutation spectrum of these populations. This comprehensive genomic landscape of breast cancer in the MENA region addresses a critical gap in global cancer genomics, ultimately improving outcomes for a historically underrepresented patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf205","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:12:05Z","timestamp":1752502325000},"source":"Crossref","is-referenced-by-count":2,"title":["Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review"],"prefix":"10.1093","volume":"30","author":[{"given":"Lama","family":"Abujamous","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University , Doha,","place":["Qatar"]},{"name":"Office of Vice President for Research and Graduate Studies, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Science, QU Health, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Ahen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Science, QU Health, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Science, QU Health, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala-Eddin","family":"Al Moustafa","sequence":"additional","affiliation":[{"name":"Oncology Department, McGill University , Montreal, Quebec H4A 3J1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereena","family":"Mohd Arif","sequence":"additional","affiliation":[{"name":"The National University of Malaysia in Qatar , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Al-Thawadi","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-3975","authenticated-orcid":false,"given":"Rozami","family":"Razali","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Science, QU Health, Qatar University , Doha,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025091815424568100_oyaf205-B1","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"key":"2025091815424568100_oyaf205-B2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2991\/j.jegh.2018.09.003","article-title":"Burden of breast cancer in the Arab world: findings from global burden of disease, 2016","volume":"1-2","author":"Jawad Hashim","year":"2018","journal-title":"J Epidemiol Glob Health"},{"key":"2025091815424568100_oyaf205-B3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13690-022-00918-y","article-title":"Burden of female breast cancer in the Middle East and North Africa region, 1990\u20132019","volume":"80","author":"Safiri","year":"2022","journal-title":"Arch Public Health"},{"key":"2025091815424568100_oyaf205-B4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ijsu.2010.05.012","article-title":"Age at diagnosis of breast cancer in Arab nations","volume":"8","author":"Najjar","year":"2010","journal-title":"Int J Surg"},{"key":"2025091815424568100_oyaf205-B5","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/cancers15061917","article-title":"What is known about breast cancer in young women?","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers."},{"key":"2025091815424568100_oyaf205-B6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.18632\/oncotarget.27909","article-title":"Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients","volume":"12","author":"Barakeh","year":"2021","journal-title":"Oncotarget"},{"key":"2025091815424568100_oyaf205-B7","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1038\/ncomms11908","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"2025091815424568100_oyaf205-B8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","article-title":"The context-specific role of germline pathogenicity in tumorigenesis","volume":"53","author":"Srinivasan","year":"2021","journal-title":"Nat Genet"},{"key":"2025091815424568100_oyaf205-B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat Rev Genet"},{"key":"2025091815424568100_oyaf205-B10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"2025091815424568100_oyaf205-B11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","article-title":"Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Discov"},{"key":"2025091815424568100_oyaf205-B12","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091815424568100_oyaf205-B13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2025091815424568100_oyaf205-B14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"key":"2025091815424568100_oyaf205-B15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/2159-8290.CD-21-1064","article-title":"Genomic landscape and clinical utility in Korean advanced Pan-Cancer patients from prospective clinical sequencing: K-MASTER program","volume":"12","author":"Park","year":"2022","journal-title":"Cancer Discov"},{"key":"2025091815424568100_oyaf205-B16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41523-022-00443-9","article-title":"High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing","volume":"8","author":"Kostecka","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2025091815424568100_oyaf205-B17","volume-title":"Genetics, Somatic Mutation","author":"Miles","year":"2022"},{"key":"2025091815424568100_oyaf205-B18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/genes10050398","article-title":"Preserving genome integrity during the early embryonic DNA replication cycles","volume":"10","author":"Kermi","year":"2019","journal-title":"Genes"},{"key":"2025091815424568100_oyaf205-B19","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025091815424568100_oyaf205-B20","first-page":"439","volume-title":"Cities of the Middle East and North Africa\u202f: A Historical Encyclopedia","author":"Michael","year":"2007"},{"key":"2025091815424568100_oyaf205-B21","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.jpainsymman.2021.09.008","article-title":"The impact of optimism on cancer-related and postsurgical cancer pain: a systematic review","volume":"63","author":"Forte","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"2025091815424568100_oyaf205-B22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyses: advantages and limitations of the newcastle ottawa scale","volume":"5","author":"Luchini","year":"2017","journal-title":"World J Meta-Anal"},{"key":"2025091815424568100_oyaf205-B23","doi-asserted-by":"crossref","first-page":"e99306","DOI":"10.1371\/journal.pone.0099306","article-title":"PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing","volume":"9","author":"Bai","year":"2014","journal-title":"PLoS One"},{"key":"2025091815424568100_oyaf205-B24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1590\/1806-9282.61.05.474","article-title":"Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis","volume":"61","author":"Encinas","year":"2015","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"2025091815424568100_oyaf205-B25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3892\/ol.2011.236","article-title":"TP53 genetic alterations in Arab breast cancer patients: novel mutations, pattern and distribution","volume":"2","author":"Al-Qasem","year":"2011","journal-title":"Oncol Lett"},{"key":"2025091815424568100_oyaf205-B26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/cbt.25945","article-title":"Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients","volume":"14","author":"Karakas","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"2025091815424568100_oyaf205-B27","doi-asserted-by":"crossref","first-page":"e2086\u20139","DOI":"10.1002\/onco.13916","article-title":"Molecular spectra and frequency patterns of somatic mutations in Arab women with breast cancer","volume":"26","author":"Al-Shamsi","year":"2021","journal-title":"Oncologist"},{"key":"2025091815424568100_oyaf205-B28","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.18632\/oncotarget.25123","article-title":"Somatic mutations in early onset luminal breast cancer","volume":";9","author":"Encinas","year":"2018","journal-title":"Oncotarget"},{"key":"2025091815424568100_oyaf205-B29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12964-024-01863-9","article-title":"Targeting mutant p53: a key player in breast cancer pathogenesis and beyond","volume":"22","author":"Qayoom","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2025091815424568100_oyaf205-B30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics."},{"key":"2025091815424568100_oyaf205-B31","author":"Davies Mark","year":"2022"},{"key":"2025091815424568100_oyaf205-B32","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025091815424568100_oyaf205-B33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2025091815424568100_oyaf205-B34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jmoldx.2022.11.002","article-title":"Assessments of somatic variant classification using the association for molecular pathology\/American society of clinical oncology\/college of American pathologists guidelines: a report from the association for molecular pathology","volume":"25","author":"Li","year":"2023","journal-title":"J Mol Diagn"},{"key":"2025091815424568100_oyaf205-B35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-\u00admutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091815424568100_oyaf205-B36"},{"key":"2025091815424568100_oyaf205-B37","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-Kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N Engl J Med"},{"key":"2025091815424568100_oyaf205-B38","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.gendis.2024.101430","article-title":"Oncogenic activation of PI3KCA in cancers: emerging targeted therapies in precision oncology","volume":"12","author":"Wang","year":"2025","journal-title":"Genes Dis"},{"key":"2025091815424568100_oyaf205-B39","doi-asserted-by":"crossref","first-page":"e000890","DOI":"10.1136\/esmoopen-2020-000890","article-title":"PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come","volume":"5","author":"De Mattos-Arruda","year":"2020","journal-title":"ESMO Open"},{"key":"2025091815424568100_oyaf205-B40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/TCRM.S251668","article-title":"Role of alpelisib in the treatment of pik3ca-mutated breast cancer: patient selection and clinical perspectives","volume":"17","author":"Chang","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"2025091815424568100_oyaf205-B41","doi-asserted-by":"crossref","first-page":"e2308807120","DOI":"10.1073\/pnas.2308807120","article-title":"\u00adTriple-negative breast tumors are dependent on mutant p53 for growth and survival","volume":"120","author":"Dibra","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025091815424568100_oyaf205-B42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Candeias","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025091815424568100_oyaf205-B43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2016.03.004","article-title":"Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells","volume":"375","author":"G\u00f6bel","year":"2016","journal-title":"Cancer Lett"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf205\/63773283\/oyaf205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf205\/63773283\/oyaf205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf205\/63773283\/oyaf205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:42:56Z","timestamp":1758224576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf205\/8203136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf205","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,15]]},"article-number":"oyaf205"}}